1. Incidence risk of PD-1/PD-L1–related pneumonia and diarrhea in non-small cell lung cancer (NSCLC) patients: a systematic review and meta-analysis of randomized controlled trials

   • Zhi-Qiang Tong
   • Dong-Yuan Wu
   • Mei Dong

   Review 10 February 2021 Pages: 1079 - 1088

   

2. The effect of tocilizumab on mortality in hospitalized patients with COVID-19: a meta-analysis of randomized controlled trials

   • Chia Siang Kow
   • Syed Shahzad Hasan

   Review 02 February 2021 Pages: 1089 - 1094

   

3. Pharmacogenetics of tamoxifen therapy in Asian populations: from genetic polymorphism to clinical outcomes

   • Tingyu Wang
   • Yitian Zhou
   • Guosheng Cao

   Review 29 January 2021 Pages: 1095 - 1111

   

4. Ivy leaf (Hedera helix) for acute upper respiratory tract infections: an updated systematic review

   • Elizabeth Sierocinski
   • Felix Holzinger
   • Jean-François Chenot

   Review Open access 01 February 2021 Pages: 1113 - 1122

   

5. Impact of computerised physician order entry (CPOE) on the incidence of chemotherapy-related medication errors: a systematic review

   • Suresh Kumar Srinivasamurthy
   • Ramkumar Ashokkumar
   • Uppugunduri Satyanarayana Chakradhara Rao

   Review Open access 23 February 2021 Pages: 1123 - 1131

   

6. The comparative impact among different intensive statins and combination therapies with niacin/ezetimibe on carotid intima-media thickness: a systematic review, traditional meta-analysis, and network meta-analysis of randomized controlled trials

   • Hongwei Li
   • Xiaolin Xu
   • Yuling Zhang

   Review 18 February 2021 Pages: 1133 - 1145

   

7. Research on Beers Criteria and STOPP/START Criteria based on the FDA FAERS database

   • Qianqian Shao
   • Yulong Xu
   • Wei Liu

   Pharmacodynamics 25 June 2021 Pages: 1147 - 1156

   

8. Teicoplanin physiologically based pharmacokinetic modeling offers a quantitative assessment of a theoretical influence of serum albumin and renal function on its disposition

   • Chie Emoto
   • Trevor N. Johnson
   • Tsuyoshi Fukuda

   Pharmacokinetics and Disposition 01 February 2021 Pages: 1157 - 1168

   

9. Once-daily 1 g ceftriaxone optimizes exposure in patients with septic shock and hypoalbuminemia receiving continuous veno-venous hemodiafiltration

   • Marta Ulldemolins
   • Carla Bastida
   • Dolors Soy

   Pharmacokinetics and Disposition 09 February 2021 Pages: 1169 - 1180

   

10. Predictive performance of parent-metabolite population pharmacokinetic models of (S)-ketamine in healthy volunteers

    • M. E. Otto
    • K. R. Bergmann
    • Michiel J. van Esdonk

    Pharmacokinetics and Disposition Open access 11 February 2021 Pages: 1181 - 1192

    

11. In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates

    • Tim Preijers
    • Laura Bukkems
    • Ron Mathôt

    Pharmacokinetics and Disposition Open access 24 February 2021 Pages: 1193 - 1200

    

12. Impact of age and gender on paliperidone exposure in patients after administration of long-acting injectable formulations—an observational study using blood samples from 1223 patients

    • Marit Tveito
    • Gudrun Høiseth
    • Robert Løvsletten Smith

    Pharmacokinetics and Disposition 22 February 2021 Pages: 1201 - 1208

    

13. EurOP²E – the European Open Platform for Prescribing Education, a consensus study among clinical pharmacology and therapeutics teachers

    • Michiel J. Bakkum
    • Milan C. Richir
    • for the Education Working Group of the European Association for Clinical Pharmacology and Therapeutics (EACPT) and its affiliated Network of Teachers in Pharmacotherapy (NOTIP)

    Pharmacoepidemiology and Prescription Open access 23 February 2021 Pages: 1209 - 1218

    

14. The impact of health literacy on beliefs about medication in a Dutch medication-using population

    • B. B. (Boudewijn) Visscher
    • B. (Bas) Steunenberg
    • J. (Jany) Rademakers

    Pharmacoepidemiology and Prescription 16 February 2021 Pages: 1219 - 1224

15. Safety profile of chimeric antigen receptor T-cell immunotherapies (CAR-T) in clinical practice

    • Giulia Bonaldo
    • Nicola Montanaro
    • Domenico Motola

    Pharmacoepidemiology and Prescription Open access 20 February 2021 Pages: 1225 - 1234

16. Construction and analysis of a database for medication errors in a pharmacovigilance centre—the Moroccan experience

    • Loubna Alj
    • Raja Benkirane
    • Rachida Soulaymani Bencheikh

    Pharmacoepidemiology and Prescription 17 February 2021 Pages: 1235 - 1246

    

17. Proposal of a Tall Man Letter list for German-speaking countries

    • Johannes Heck
    • Adrian Groh
    • Olaf Krause

    Letter to the Editor Open access 27 January 2021 Pages: 1247 - 1249

18. Correction to: CYP3A5 and CYP3A7 genetic polymorphisms affect tacrolimus concentration in pediatric patients with nephrotic syndrome

    • Hongxia Liu
    • Qinxia Xu
    • Xiaoyan Qiu

    Correction 30 January 2021 Pages: 1251 - 1252

19. Correction to: Potentially inappropriate medication in acute hospitalized elderly patients with polypharmacy: an observational study comparing PRISCUS, STOPP, and Beers criteria

    • Lorena de Agustín Sierra
    • Jaime Rodríguez Salazar
    • Benito García Díaz

    Correction 04 February 2021 Pages: 1253 - 1253

20. Correction to: Iron chelation may harm patients with COVID-19

    • Michael D. Garrick
    • Andrew J. Ghio

    Correction 17 March 2021 Pages: 1255 - 1255

21. Correction to: Estimation of a preliminary therapeutic reference range for children and adolescents with tic disorders treated with tiapride

    • Stefanie Fekete
    • K. Egberts
    • M. Gerlach

    Correction Open access 28 May 2021 Pages: 1257 - 1257